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Abstract
T cell activation requires formation of a tri-molecular interaction between a major histocompatibility complex (MHC),
peptide, and T cell receptor. In a common model system, the ovalbumin epitope 323–339 binds the murine class II MHC, I-
Ad, in at least three distinct registers. The DO11.10 T cell recognizes the least stable of these, as determined by peptide-MHC
dissociation rates. Using exogenous peptides and peptide insertions into a carrier protein in combination with IL-2 secretion
assays, we show that the alternate registers do not competitively inhibit display of the active register four. In contrast, this
weakly binding register is stabilized by the presence of N-terminal flanking residues active in MHC binding. The DO11.10
hybridoma is sensitive to the presence of specific wild-type residues extending to at least the P-3 peptide position. Transfer
of the P-4 to P-2 flanking residues to a hen egg lysozyme epitope also presented by I-Ad increases the activity of that
epitope substantially. These results illustrate the inherent complexity in delineating the interaction of multiple registers
based on traditional thermodynamic measurements and demonstrate the potential of flanking residue modification for
increasing the activity of weakly bound epitopes. The latter technique represents an alternative to substitution of anchor
residues within a weakly bound register, which we show can significantly decrease the activity of the epitope to a
responding T cell.
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Introduction
The adaptive immune system responds to foreign proteins
through the use of cytotoxic (CD8+) and helper (CD4+) T cells that
activate and direct other effectors to mount a protective response.
These T cells are activated after a productive interaction between
the membrane bound T cell receptor (TCR) and the surface of
cells presenting a composite peptide/major histocompatibility
complex (pMHC). Crystal structures have revealed regular
patterns of peptide-MHC interactions [1], enabling prediction of
peptide epitopes present within larger proteins. CD8+ T cells
recognize Class I MHC molecules displaying 8–10 residue long
peptides derived from intracellular proteins, proteolytically pro-
cessed to a defined length in order to fit within the closed MHC
binding groove. In contrast, CD4+ T cells recognize extracellular
material that has been internalized, processed and displayed as
variable length peptides in complex with heterodimeric Class II
MHC molecules on professional antigen presenting cells. Because
of an open-ended peptide-binding groove, Class II MHC typically
display peptides with 15–20 or more residues, with the termini
extending out from the binding groove [2]. These longer peptides
present distinct challenges for epitope prediction since they
potentiate multiple modes of interaction with the MHC [3,4].
Class II peptides bind the MHC in an extended, polyproline II-
like conformation, flanked by two antiparallel a-helices, one from
each MHC chain [5]. These helices form a conserved network of
hydrogen bonds with the peptide backbone spanning the length of
the binding pocket that dictates a sequence independent confor-
mation of the displayed peptide. The stability of a specific peptide
is determined by side chain interactions with these helices as well
as internal binding pockets. The peptide rests atop a series of
pleated beta sheets, which form four prominent binding pockets,
named for the respective positions within the peptide of the
residues that occupy them: P1, P4, P6 and P9. The stretch of nine
amino acid residues spanning these pockets is referred to as the
peptide core, and the residues filling these pockets as anchor
residues. Considerable effort in class II epitope prediction has
focused on defining anchor residue preferences for specific MHC
alleles [6]. The remaining residues within the core orient their side
chains toward the helices or away from the MHC, in order to
interact with the TCR.
Within the longer peptides presented by class II MHC, multiple
core sequences may overlap, such that a single pMHC complex
may heterogeneously present multiple cores for display to
responding T cells. Murine class II I-A alleles appear particularly
susceptible to this phenomenon as anchor preferences are ill-
defined among the diverse set of known binding peptides. The
apparent degeneracy of I-A alleles emphasizes the need for epitope
prediction models that incorporate the contributions of separate
registers within a single epitope. Indeed, early sequence-based
prediction models found that incorporation of flanking residues
outside of the predicted core improved predictions for HLA-DQ,
the human homolog of I-A [7]. This appears partially attributable
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to flanking residues either interacting directly with MHC or
influencing intracellular epitope processing [8]. More recent
models have continued to incorporate flanking residues in
sequence-based prediction models [4,9,10], with some explicitly
including flanking residues for their roles in alternate register
binding [3,4].
The I-A gene is associated with numerous autoimmune mouse
models, while the homologous HLA-DQ is associated with insulin
dependent diabetes milletus, celiac disease, and potentially
multiple sclerosis in humans (Jones et al., 2006; Kaushansky et
al., 2009). This allele-specific autoimmune susceptibility may result
from peptide presentation in multiple registers [11]. In this
proposed mechanism, auto-reactive T cells escape thymic deletion
because their target self-epitopes are hidden by ‘‘register masking,’’
whereby they are presented less frequently than more thermody-
namically stable alternate registers within the same proteolytic
fragment. Thus, T cells responding to the more stable registers are
deleted, while those responding to less stable registers migrate to
the periphery. At the site of inflammation, where the peptide is
highly expressed, the weaker register will be presented with
sufficient frequency to activate self-reactive T cells and induce
disease. Specific epitopes identified in the NOD mouse model of
type 1 diabetes [12] as well as experimental autoimmune
encephalomyelitis [13–15] have been identified as potentially
susceptible to this mechanism.
The DO11.10 T cell hybridoma is a popular model system used
to study CD4+ T cell responses, originally elicited by vaccination
of Balb/c mice (H-2d haplotype) with hen egg white ovalbumin
(OVA). The specific peptide recognized was originally described as
the tryptic fragment corresponding to residues 323–339 as
presented by I-Ad [16]. Subsequent studies first identified two
distinct binding registers within this long peptide (324–332; 327–
335) [17]. Later, a third register was identified (329–337) and a
fourth proposed (326–334; Table 1) [18]. Among these, the
DO11.10 T cell hybridoma was shown to recognize the C-terminal
register (residues 329–337, referred to hereafter as register four)
through the use of N- and C-terminal truncations and targeted
amino acid substitutions [18]. The failure of MHC tetramers with
a covalently linked 323–339 peptide to stain DO11.10 and other
peptide-specific T cells has driven interest in further defining the
register recognized. Recently, Landais et al. synthesized four
tetramers, each presenting one of the four respective nine residue
core sequences present within the 323–339 peptide, and confirmed
that only the register four peptide stained DO11.10 cells and
bound the free T cell receptor [19].
Peptide-MHC complex stability correlates broadly with immu-
nogenicity [20,21], as stable epitopes are more prevalent on the
cell surface, and subsequently more likely to be recognized by
responding T cells. Stability is commonly approximated as the
dissociation rate of fluorescently labeled peptide from soluble
MHC, although this approach can be complicated by highly
overlapping registers. McFarland et al. showed that OVA registers
one and three are long-lived and stable [17]. Supporting the
thermodynamic stability of register one, a complex between the
323–339 peptide and I-Ad was crystallized in that register [22],
and tetramers with long, unhindered covalent linkers primarily
inhabit register one [19]. In contrast, the DO11.10-responsive
register four peptide has a very rapid off-rate, with a half-life of
around twenty minutes [21]. To minimize alternate register effects
confounding this measurement, the amino acid sequence flanking
the register four core was truncated at P-2 on the N-terminus, with
the P-2 position altered from valine to lysine, which is presumably
too large to stably occupy the P1 binding pocket. These peptide
dissociation rates predict that register four would behave as a
masked, cryptic epitope, albeit in the context of a foreign antigen.
Despite this kinetic data, seemingly contradictory accounts have
emerged as to whether register four is masked in vivo by its
overlapping counterparts. Two reports observed that register four
specifically elicits relatively few responding T cells [21,23]. In
contrast, Landais et al. found that pMHC tetramers presenting
only the fourth register stained a significantly greater number of
responsive T cells following OVA immunization than tetramers
presenting the more stable first and third registers [19].
Here, we set out to quantify the extent to which registers one
and three mask display of the active register four, using synthetic
OVA peptides incorporating truncations and/or amino acid
substitutions to alter presentation of a given register and,
ultimately, to enhance register four display. Recombinant proteins
harboring internal peptide variants were employed to capture
effects associated with epitope processing. After incubation of
DO11.10 hybridomas with corresponding B-cells and a peptide
variant, we measured T cell activation in terms of IL-2 secretion,
as the most sensitive determinant of register four’s accessibility to
responsive T cells.
We observed that presentation of register one, but not register
three, is independent of register four activity. Disruption of register
one through N-terminal peptide truncation had no impact on
measured activity. Residues thought to be primarily involved with
register three binding, on the other hand, proved essential for
activity. Wild type residues 325–327 (QAV; P-4 through P-2) were
necessary for complete activation. Transfer of these flanking
residues to identical positions on an unrelated hen egg white
lysozyme epitope, HEL11–25, increased the activity of that
epitope dramatically, based on EC50 and maximal response. This
Table 1. Alternate registers within OVA 323–339.
Register
Register
identified (ref) Dissociation rate constants
a
P-4 P-3 P-2 P-1 P1 P2 P3 P4 P5 P6 P7 P8 P9 peptide used (kd, s
21)
1 (324–332) I S Q A V H A A H A E I N E A 24 323–335 Q325Ab 0.02361024
2 (326–334) I S Q A V H A A H A E I N E A G R 20 na na
3 (327–335) I S Q A V H A A H A E I N E A 19 325–336 0.02661024
4 (329–337)I S Q A V H A A H A E I N E A G R 20 327–339 V327Kc 661024
aApparent first order dissociation constants of presumed isolated registers from purified I-Ad for: single exponential fits to monophasic dissociation data (registers 1,3,
ref 19), or back-calculated from reported half-life of dissociation (register 4, ref 23).
bAlanine was substituted at position 325 to avoid formation of demonstrated dissociation intermediate.
cLysine was substituted at position 327 to avoid alternate register binding.
doi:10.1371/journal.pone.0047585.t001
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suggests that these residues independently stabilize peptide-I-Ad
interactions and that, consequently, register four stability has been
underestimated by techniques truncating these flanking residues.
Attempts to determine the precise effect of the adjacent register
three stability on activity of the weaker register four using anchor
substitutions were inconclusive. Collectively, our results indicate
that flanking residues can affect activity to a previously unforeseen
extent. These results have broad implications for class II epitope
prediction algorithms and protein engineering efforts to modulate
protein immunogenicity in therapeutics and vaccines. In partic-
ular, the engineering of flanking residues may increase the stability
of weakly bound epitopes for use in vaccination strategies and the
manipulation of immunogenicity within proteins.
Results
DO11.10 Activation is Modulated by Epitope Anchor
Residues Substitutions
The rapid dissociation of register four relative to the other
registers within 323–339 led us attempt to increase peptide activity
through a corresponding increase in register four affinity for I-Ad.
The poor stability of register four is likely due to the weakly
binding anchor residues at ovalbumin positions A329, A332, I334,
A337 (Table 1). Anchor substitution is a common technique for
increasing the affinity of a given register; previously, Chaves et al.
reported the relative stability of commonly observed anchor
residues with I-Ad [24]. In this and other work, the interactions of
each anchor residues with its respective binding pocket were found
to be independent of the overall sequence [3].
Two previous reports described anchor substitutions to stabilize
register four. Robertson et al. replaced all four positions with the
corresponding anchor residues from a sperm whale myoglobin
epitope possessing high affinity for I-Ad as follows: A329E, A332I,
I334V, A337S (the resulting peptide is referred to here as 323–339
EIVS) [18], and reported increased activity for the variant.
Similarly, Lazarski et al. reported hybridoma recognition of a
variant incorporating two of these substitutions, A332I and I334V
(here called 327–339 KIV), as well as a V327K substitution
intended to prevent register shifting to the more stable third
register via incompatibility of the bulky lysine with the P1 pocket
[21]. To assess the relative success of these attempts, we
synthesized both variants, along with an N-terminally truncated
version of the Robertson peptide (328–339 EIVS; Table 2) to
remove the effects of flanking residues which we hypothesized
would promote register masking. To assess peptide activity,
DO11.10 hybridomas were incubated for 24 hours with I-Ad+
A20 lymphoma cells in the presence of peptide, and supernatant
was subsequently assessed for the presence IL-2 by a matched pair
ELISA as a measure of T cell activation. Surprisingly, all three
peptide variants drastically reduced T cell stimulation versus 323–
339 (Figure 1A). Given the documented affinity increase of 327–
339 KIV for I-Ad [21], the decrease in T cell stimulation
associated with these variants likely results from interference in
TCR/pMHC recognition due to minor structural variations.
DO11.10 Stimulation Modulated by Residues N-terminal
to P-2
The failure of anchor four residue substitutions to increase
activity led us to explore N-terminal truncations alone as a means
to destabilize alternate registers, which may compete with register
four for MHC binding. The 323–339 peptide was progressively
truncated from the N-terminus, with each truncated peptide
extending to an amidated residue 337 and each peptide variant
incubated with DO11.10 and A20 cells, as above. The 325–337
peptide, lacking the P-1 and P1 positions of register one, conferred
identical stimulation in comparison to the 323–339 peptide, in
terms of the 50% effective concentration (EC50) and maximal
response, suggesting that register one does not effectively compete
with register four for display (Figure 1B, Table 2).
Further truncations intended to destabilize register three
reduced activity dramatically. The 327–337 peptide lacks positions
P-3 and P-4 relative to the active register, which would seem too
distant to be relevant, yet the EC50 increases nearly 10-fold, from
1.6 to 12 mM peptide while the maximal response decreases from
1.1 to 0.7 ng/mL IL-2. For the 328–337 peptide, further lacking
position P-2, activity is so severely reduced that accurate EC50
values could not be determined (Table 2). These data agree
qualitatively with Robertson et al. who measured T cell
proliferation from transgenic DO11.10 mice in response to a
similar set of truncated peptides [18]. DO11.10 stimulation is thus
found to be maximal when in addition to active register four, the
presumably competing third register (residues 327–335) is
completely present along with at least one additional N-terminal
residue.
The necessity of these distant flanking residues lends itself to
three possible explanations. (1) The necessity of these flanking
residues is a result of their direct interaction with the responding T
cell. (2) Despite their distance from the active register, these
residues stabilize it by means of non-traditional interaction with
the MHC. (3) The primary role of these flanking residues is to
stabilize register three, which on the whole cooperatively
promotes, rather than competitively inhibits, display of register
four.
DO11.10 Flanking Residues Increase Activity upon
Transfer to HEL1125 Peptide
In order to test these competing hypotheses, we employed an
unrelated peptide epitope from the hen egg white lysozyme protein
(HEL), which is presented by the same MHC (I-Ad) as the
ovalbumin peptide to a distinct responding T cell [25]. A survey of
the available pMHC crystal structures reveals that the T cell
receptor can, by virtue of its CDR1a and CDR3a loops, contact
presented flanking residues in the P-1 position and occasionally at
more distant flanking positions [1]. MHC contacts, on the other
hand, appear to be more predictable, and are typically limited to
canonical hydrogen bonds between residue P-1 and the side chain
of b81H or Y, as well as residue P-2 and the main chain of a53
[26].
The HEL epitope consisting of residues 11 through 25 (HEL11-
25) has been characterized as a weak MHC binder when
presented by I-Ad, with a short half-life of approximately six
hours [21] that presumably results from a poorly accommodated
arginine side chain in the P1 pocket. We compared the activities of
wild type HEL11-25 to a variant in which the native P-4 to P-2
sequence was replaced with OVA-specific residues (QAV13-25)
and a control in which these three residues were adjusted to GGS
(GGS13-25). Since these changes lengthen the HEL11-25 peptide
by a single amino acid, a control in which the HEL11-25 peptide
was appended with an N-terminal glycine in position P-3 (G11-25)
was also analyzed. We reasoned that if the variant including the
OVA flanking residues (QAV13-25) showed increased activity, it
would increase the likelihood that these flanking residues are
interacting with the presenting MHC, rather than the distinct
responding TCR.
Interestingly, the QAV13-25 variant significantly increases HEL
peptide activity, with the EC50 decreasing two-fold, from 6 to
3 mM peptide, while the maximum response increases two-fold,
from 0.7 to 1.5 ng/mL IL-2. In contrast, the control peptides
Flanking Residues Enhance Cryptic Epitope Response
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exhibit minimal or no change in activity, as measured by EC50 and
maximal response (Figure 2; Table 3). The OVA flanking residues
at positions P-4 through P-2 independently increase peptide
activity in a manner independent of the specific T cell receptors
involved, which does not support hypothesis one above. It does,
however, support hypothesis two and a direct role for the QAV N-
terminal flanking residues in stabilizing the peptide-MHC
interaction. In addition, HEL11-25 has not been shown to occupy
multiple frames in I-Ad, thus reducing the possibility that flanking
residues are relevant in any role apart from stabilization of the
active register (hypothesis three). Collectively, these data support
hypothesis two over the proposed alternatives.
Peptide Activity is Specific to Wild Type Residues N-
terminal to P-2
To further clarify the role of residues 325 and 326 in the register
four interaction with I-Ad, we examined the necessity of wild type
identities in these positions. Published crystal structures show
conserved hydrogen bonds between main chain amino acids of
presented peptides at positions P-1, with the side chain of histidine
or tyrosine at b81 of the MHC, and P-2, with the main chain of
a53. Observed hydrogen bonds and van der Waals interactions
between MHC and more distant N-terminal flanking positions are
irregular and rare.
We replaced the Q325 and A326 residues with glycine in a
synthetic peptide (GGV328-337). Glycine was selected over
alanine because of the latter’s propensity to occupy I-Ad anchor
positions, as well as the presence of alanine at position 326 in the
native epitope. The resulting variant GGV328–337 was more
active than the shorter 327-337 peptide (EC50 = 6 and 12 mM,
respectively), but remained three-fold less potent than 325-337
(EC50 = 2 mM; Figure 1C, Table 2), both differences are statisti-
cally significant (p,0.01). For DO11.10, peptide activity is
somewhat dependent on wild-type residues extending at the N-
terminus to at least the register four P-3 position (residue 326).
Carrier Proteins Presenting Variant Peptides Recapitulate
Synthetic Peptide Results
To confirm the peptide results and explore their relevance in the
context of the native Class II peptide display process, we
introduced select peptide variants into a carrier protein, maltose
binding protein (malE). If flanking residues are involved in register
four stabilization through MHC interaction, then their presence
should have the same effect in fusion proteins as in exogenous
peptides. However, processing and subsequent presentation has
Figure 1. Specific flanking residues but not alternate register stabilization enhances OVA peptide activity. DO11.10 hybridoma and
antigen presenting cells were incubated overnight in the presence of exogenous peptide variants, followed by quantification of IL-2 released as a
measure of T cell activation. A,Wild-type ovalbumin 323–339 (N) was compared with peptide variants modified at anchor residues P4 (A to I) and P6
(I to V) in conjunction with additional changes in an effort to stabilize the active register four. Peptide variants include 327-339KIV (&) with an
additional N-terminal truncation and P-2 modification (V to K) to prevent register shifting; 323-339EIVS (m) the full-length peptide with all four anchor
residues altered to strongly binding residues; and 328-339EIVS, an N-terminal truncation of the previous variant (.). The cell culture media contained
2 mM glutamine for this assay. B, In a subsequent effort to stabilize register four by removing alternate register anchors, the wild-type 323–339
peptide (N) was compared with N-terminally truncated variants 325–337 (&), 327–337 (m), and 328–337 (.). C, To determine whether peptide
length is responsible for the activity differences observed in the truncated variants, the 325–337 variant (&) which includes register four and the N-
terminal P-1 to P-4 residues was compared with GGV328–337, in which the P-3 and P-4 positions were replaced with glycine (X) and a further
truncated variant, 327–337 (m), lacking the P-3 and P-4 residues. D, To determine whether binding of register three enhances register four activity, we
changed the register three P1 anchor residue (also register four P-2) to amino acids predicted to stabilize (M) or destabilize (S) register three. We
compared three variants with identical length: variant GGV328–337 (X) with a wild-type V versus GGS328–337 ( ) and GGM328–337 ( ). Data were
fit to three-parameter curves with Graphpad Prism and are representative of three independent experiments; error bars show standard deviation of
triplicate wells assayed for a given peptide concentration.
doi:10.1371/journal.pone.0047585.g001
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been reported to eliminate display of weaker pMHC conformers
observed during exogenous peptide display via the MHC Class II-
like endosomal protein H2-DM [25,27–30]. We wondered
whether the presentation of register four and stabilization via
distant flanking residues was the result of a conformer uniquely
achieved in the context of exogenous peptides, one that might be
hindered by more stable competing registers when subjected to
endosomal MHC loading conditions.
Peptide sequences were introduced into the exposed loop in
place of residues 133–140 as first described by Martineau et al.
[31], with a glycine-serine extension (GSGSG) appended to the N-
terminus of inserted epitopes to increase solubility (Figure 3A,
Table 4). The activity of the N-terminally truncated peptides in
MBP (325–337, 327–337, 328–337) indicates a maintained
preference for wild type flanking residues as was previously
observed with synthetic peptides (Figure 3A, Table 4). The wild-
type 323–337 and 325–337 inserts have EC50 within error (13 mM
with a max signal of 0.8 ng/mL and 18 mM protein with a max
signal of 1.1 ng/mL, respectively) while the activities of the 327–
337 and 328–337 variants are greatly reduced (EC50 of 41 and
73 mM, with max signals of 0.6 and 0.3 ng/mL, respectively). The
increased activity of variants retaining the wild type P-3 and P-4
residues of register four during intracellular processing again
supports their direct role in mediating the peptide and MHC
interaction.
Substitutions at Position 327 Enhance Peptide Activity
within a Carrier Protein
Register four stabilization by distant flanking residues, shown
above, does not preclude the involvement of register three in
cooperatively increasing the presentation of the active register
(hypothesis three), or inhibiting it, for that matter. After all,
residues 325–327 would, according to traditionally understood
peptide-MHC interactions, be more likely to act as P-2 through P1
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Figure 2. Ovalbumin flanking residues enhance HEL11-25
peptide activity. HEL11-25 hybridoma cells and antigen presenting
cells were incubated overnight in the presence of exogenous peptide
variants, followed by quantification of IL-2 release as a measure of T cell
activation. The wild type HEL11-25 peptide (N) is compared to a longer
variant with an additional G at position P-4, G11-25 (&); an additional
control variant in which the P-2 to P-4 flanking residues have been
replaced with GGS, GGS13-25 (m); and a variant presenting the
ovalbumin- flanking residues in positions P-4 to P-2, QAV13-25 (.).
Data were fit to three-parameter curves with Graphpad Prism and are
representative of three independent experiments; error bars show
standard deviation of triplicate wells assayed for a given peptide
concentration.
doi:10.1371/journal.pone.0047585.g002
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of register three than as P-4 through P-2 of register four. We thus
sought to specifically probe the impact of changes in the relative
stability of register three on the activity of register four.
Initially, we introduced substitutions for valine at position 327 to
modulate register three stability. Among the candidate register
three anchor residues (V327, A330, A332, N335), the P1 position
occupied by V327 is the only anchor not overlapping with the
register four core (329–337). Previously, residue substitutions in
the spacious first binding pocket of I-Ad have been shown to have
drastic impacts on register stability [24]. For the carried peptide,
two variants of the malE 327 were created with strong predicted P1
anchors for register three: 327 V(-2)M and 327 V(-2)E. The
negatively charged glutamic acid side chain contrasts with the
nonpolar methionine in potential contributions to solubility and
protease accessibility, but both are strongly preferred in the P1
binding pocket [24]. Both protein variants enhanced activity of the
processed epitope about two-fold, based on EC50 values (18 and
25 mM for the variants versus 41 mM for the native 327–337 fusion
protein; Figure 3B), possibly indicating a positive relationship
between register three stabilization and register four activity.
Increased Activity of Position 327 Mutants is not
Dependent on H2-DM
During peptide loading onto the MHC in the endosomal
compartment, the class II-like H2-DM protein modulates the
repertoire of displayed peptides [28,30]. To examine whether the
activity of our chimeras depends on H2-DM activity, we
substituted 3A5, a variant of the A20 cell line with an inactivated
H2-DMa chain [34,35] in our stimulation assays. While these
experiments were less sensitive, the relative activities of the peptide
variants were consistent with A20 experiments for the peptide
length controls (Figure 4A). Likewise, the enhanced activity of
methionine and glutamic acid substitutions at position 327 was
maintained during processing by these cells (Figure 4B).
Overall, the use of the malE carrier protein to mediate peptide
presentation supports the role of flanking residues in stabilizing
register four presentation, with sequence preferences maintained
upon intracellular processing in a H2-DM-independent manner.
This supports a role for flanking residues in interacting with the
MHC, either through stabilizing the recognized conformer or an
intermediate binding state.
Increased Activity of Position 327 Mutants is not
Replicated in Free Peptides
To confirm the relationship between register three stability and
register four activity seen in position 327 variants in chimeras
above, we made similar changes in the free peptide. Two variants
of GGV328–337 were created with substitutions at the 327
Table 3. Sequences and activities of HEL peptide variants.
Peptide 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
EC50 (mM
peptide)
95%
Confidence
Max response
(ng/ml IL-2)
95%
Confidence
HEL11-25 A M K R H G L D N Y R G Y S L 6 2–20 0.7 0.3–1.1
G11-25 G A M K R H G L D N Y R G Y S L 7 2–23 0.7 0.3–1.1
QAV13-25 Q A V K R H G L D N Y R G Y S L 3* 1–6 1.5* 0.9–2.1
GGS13-25 G G S K R H G L D N Y R G Y S L 6* 2–26 0.5* 0.2–0.8
EC50 and maximum response values from 3-parameter curve fits of aggregate data from multiple (at least two) experiments.
*p,0.01 by extra sum of squares f-test of curve fits for antigen vs. control (HEL11–25 for HEL peptides). Comparisons performed only on data from assays in which both
antigens were tested (minimum of two independent assays).
doi:10.1371/journal.pone.0047585.t003
Figure 3. Specific flanking residues and register three enhance
Ova peptide activity when endogenously processed as malE
chimeras. DO11.10 hybridoma and A20 antigen presenting cells were
incubated overnight in the presence of malE chimeras containing
ovalbumin epitope variants, followed by quantification of IL-2 release as
a measure of T cell activation. A, Comparison of wild-type peptide 323–
337 insert (N) with N-terminally truncated variants lacking alternate
register anchor positions: 325–337 (&), 327–337 (m), and 328–337 (.).
B, A truncated control peptide including the entire register four and
register three, 327–337 (m) was compared with variants in which the
register three P1 anchor was altered in order to increase this registers
stability: 327 V(-2)M (X) and 327 V(-2)E ( ). Data were fit to three-
parameter curves with Graphpad Prism and are representative of two
independent experiments; error bars show standard deviation of
triplicate wells assayed for a given protein concentration.
doi:10.1371/journal.pone.0047585.g003
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position (P1 for register three): one in which the valine was
replaced with a methionine (GGM328–337), and a second in
which the valine was replaced with serine (GGS328–337), which
can act as an anchor, but poorly occupies P1 [22]. If register four is
cooperatively aided by register three binding, we would expect
peptide activity to correlate with P1 anchor preference, such that
GGM . GGV . GGS. In the case of the free peptides GGS328–
337 shows two-fold reduced EC50, consistent with this weak
relationship. However, GGM328–337 is nearly identical in
activity to GGV328–337 (Figure 1D; Table 2).
Presentation of register four may be limited by the more
stringent competition for MHC binding between a variety of
epitopes during endogenous peptide loading. In general, greater
concentrations of the carrier protein are needed to achieve the
same stimulation as with exogenous peptides (Table 4). In addition
to the invariant chain peptide, which shows relatively high affinity
for I-Ad [32], malE itself contains several immunogenic determi-
nants with which the inserted epitope must compete [33].
However, the failure of GGM328–337 to improve activity may
indicate that substitutions at position 327 have an effect distinct
from increasing register three stability. Direct measurement of
peptide dissociation rates between I-Ad and P1 variants derived
from malE fusion proteins from is complicated by the same
overlapping registers inherent in the wild type peptide. In the
absence of reliable kinetic data, it is impossible to know for sure
whether predicted changes in register three stability as a result of
position 327 substitutions were actually realized. The absence of
strict agreement between predicted changes in register three
stability and peptide activity somewhat weakens the case for
cooperativity between the two registers.
Molecular Docking Predicts Registers 1 and 3 Interactions
with MHC
To further probe the connections between binding registers and
flanking residue interactions with the MHC, we used the
molecular docking program ClusPro in conjunction with the
experimental I-Ad structure to predict peptide-MHC interactions
[36]. Subsequent docking of the OVA peptide yielded high scoring
structures with the peptide oriented in register one as seen in the
crystal structure, and register three, but neither registers two nor
four (Supplementary Figure 1).
Discussion
Of the four registers present within the ovalbumin 323–339
peptide, the first register (residues 324–332) forms the most
kinetically stable complex with MHC [17], is preferentially
presented in I-Ad tetramers [19], and has been crystallized [22].
When N-terminally truncated to position 325, the peptide can no
longer occupy this first register due to the absence of the register
one P1 anchor and P-1 flanking residue [17]. Yet in the presence
of the responsive DO11.10 hybridoma, 325–337 is no more active
than the full-length version, indicating that register one does not
competitively inhibit display of the active register four. In contrast,
the presence of an intact register three enhances peptide activity
relative to the isolated register four: the activity of the short 328–
337 peptide is lower than that of the 327–337 peptide, which is in
turn lower than the 325–337 peptide.
Our efforts to dissect OVA 323–339 interactions with MHC led
us to conclude that register four presentation depends upon distant
flanking residues interacting with I-Ad (Figure 5). This is based on
the observations that wild type residues extending to at least P-3
are necessary for maximum activity, and the interaction of
flanking residues with the presenting MHC generalize to the
HEL11–25 peptide. Substitution of P-4 and P-2 residues into the
distinct I-Ad epitope, HEL11–25, dramatically increases peptide
activity when presented to a responsive T cell hybridoma. Within
the available peptide/MHC crystal structures, flanking residues
form hydrogen bonds and van der Waals contacts with the MHC,
commonly with P-1 and P-2, but interactions at P-3 and beyond
are not unprecedented [39–45].
The common practice of truncating or substituting flanking
residues may explain why register four has been reported to be
both ineffective at producing T cell responders [21,23], and
immunodominant [19]. These modifications may have also
resulted in artifactually weak estimates of peptide dissociation
rates. These measurements used a minimal register four peptide
truncated at position 327, with 327 itself altered from valine to
lysine (327–339 KIV) [21] to eliminate register three effects. Since
these changes also remove or alter P-4 to P-2 flanking residues we
have shown to be critical for activity, use of this minimal peptide
likely results in a much faster off-rate than is relevant for the larger
323–339 peptide.
Despite the observation that distant flanking residues are
important for register four presentation, this does not resolve all
Table 4. Sequences and activities of peptide variants in MalE carrier protein.
MalE
chimera 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339
EC50 (mM
peptide)
95%
Confidence
Max response
(ng/ml IL-2)
95%
Confidence
323–337 I S Q A V H A A H A E I N E A 13* 8–20 0.8* 0.6–1.0
325–327 Q A V H A A H A E I N E A 18* 12–25 1.1* 0.9–1.4
328–337 H A A H A E I N E A 73* 26–201 0.3* 0.1–0.5
327–337 V H A A H A E I N E A 41 27–61 0.6 0.5–0.8
327 V(-2)M M H A A H A E I N E A 18* 13–25 1.0* 0.8–1.2
327 V(-2)E E H A A H A E I N E A 25* 15–44 0.7* 0.5–1.0
EC50 and maximum response values from 3-parameter curve fits of aggregate data from multiple (at least two) experiments. Positional numbering is in relation to the
active register (register four in the case of OVA).
*p,0.01 by extra sum of squares f-test of curve fits for antigen vs. control (MalE 327–337 for MalE chimeras). Comparisons performed only on data from assays in which
both antigens were tested (minimum of two independent assays).
doi:10.1371/journal.pone.0047585.t004
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questions surrounding the epitope. Although we suspect that the
stability of the active register has been previously underestimated,
this is probably insufficient to eliminate competition from the
stable registers one and three. Why then, do we not observe
masking of the register four in presentation to the hybridoma?
Register masking has attracted increasing attention in recent
years as a mechanism for promoting autoimmunity via incomplete
thymic education. For instance, the weakly bound myelin basic
protein epitope (MBP Ac1–9) is flanked at the C-terminus by a
more stable register [13,15], as well as at the N-terminus in the
golli-form of MBP expressed in the thymus [14]. Maverakis et al.
observed direct competition between registers for MHC binding,
as presentation of each register was reduced by the presence of an
alternate register, as measured by T cell stimulation. In the non-
obese diabetic mouse model of type 1 diabetes, the insulin B 9–23
peptide was also found to bind in multiple registers [37,38], with
the least stable register apparently activating pathogenic T cells
[12]. Understanding the distinction between these epitopes and
the apparently unmasked register four of OVA 323–339 is likely
prove insightful in the future investigation of autoimmunity.
In seeking to understand the lack of register masking in 323–
339, we attempted to directly manipulate the stability of register
three through amino acid substitutions and observe its effect on
register four activity as measured by hybridoma stimulation.
Figure 4. H2-DMa is not responsible for the different activities
of endogenously processed peptide variants. DO11.10 hybrid-
oma and 3A5 antigen presenting cells containing mutant H2-DMa
gene, were incubated overnight in the presence of malE chimeras
containing ovalbumin epitope variants, followed by quantification of IL-
2 release as a measure of T cell activation. A, To assess the effects of
removing alternate register anchor positions, truncated ovalbumin
peptide inserts 325–337 (&), 327–337 (m), and 328–337 (.) were
compared. B, To assess the effect of stabilizing register three with P1
anchor substitutions, the control peptide 327–337 (m) was compared
with variants 327 V(22)M (X) and 327 V(22)E ( ), substitutions which
have been shown to confer enhanced I-Ad binding. Curve fits for the
latter two are nearly identical, and lie atop one another. Data were fit to
three-parameter curves with Graphpad Prism and are representative of
two independent experiments; error bars show standard deviation of
triplicate wells assayed for a given protein concentration.
doi:10.1371/journal.pone.0047585.g004
Figure 5. Cartoons depicting the tripartite interactions be-
tween the DO11.10 TCR, I-Ad MHC and the OVA 323–339
peptide in various registers. A, The peptide is shown in register
three, with the MHC anchor residues (P1, P4, P6 and P9) extending
towards the MHC and residues interacting with the TCR (primarily P5
and to a lesser extent, P2 and P8) extending towards the TCR. B, The
peptide is shown in register four, with MHC anchor residues and TCR
residues shown as above. The cartoon MHC has been modified to
indicate potential interaction with flanking residues extending as far as
P-4.
doi:10.1371/journal.pone.0047585.g005
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Methionine and glutamic acid substitutions at position 327
predicted to stabilize register three actually increased the activity
of register four when processed from a malE carrier protein and
presented by A20 cells. This raises the intriguing possibility that
register four display is cooperatively enhanced by a stable register
three. However, methionine substitution at 327 in the context of
an exogenous peptide did not increase activity. Given our
uncertainty at whether substitutions actually produced the desired
register three stabilization, and the difficulty of measuring this
stabilization in the face of entangling register kinetics, we cannot
claim with sufficient confidence that such a cooperative effect
exists.
As a final note, our finding that the anchor substituted peptide
323–339 EIVS severely diminished activity contrasts with the
report of Robertson et al. [18]. Many reports have described
successful increases in biological activity via anchor swaps,
particularly for CD8+ T Cells [47–53]. However, the effect seems
far from general, as several other reports have shown the opposite
effect include [43,54,55]. Notably, our work is consistent with
Landais et al., who generated I-Ad tetramers with the register four
329–337 peptide and observed reduced DO11.10 staining when
the chemically distinct P1 substitutions A329M or A329E were
introduced [19]. The discrepancy with Robertson et al. may be
attributable to assay differences: measurement of hybridoma IL-2
secretion versus their DO11.10 transgenic T cell proliferation. In
summary, this result highlights the sensitivity of the DO11.10
TCR to even small conformational changes introduced within the
core. Inconsistency in anchor residue substitution effects among
different peptides makes the prospect of stabilization through
substitution of flanking residues all the more enticing.
Conclusions
Overall, our findings support inclusion of residues outside the
nonameric core and multiple, distinct registers in epitope
prediction models [3,4,9,10]. The ability of the ovalbumin flanking
residues to confer enhanced activity to an unrelated HEL11–25
peptide may have general applications for understanding peptide
immunogenicity and stability. In terms of the specific ovalbumin
323–339 peptide, our attempts to increase peptide activity through
register four anchor substitutions severely diminished activity.
Anchor substituted peptides may be more prone to influencing T
cell response, as compared to flanking residue changes which are
more distal to primary T cell contacts. Modification of flanking
residues may increase activity of a weakly bound peptide while
minimizing changes in the responding T cell repertoire. Recently
described high throughput techniques [56], are likely to be
instrumental in identifying stabilized variants of weakly bound
peptides for use as altered peptide ligands in autoimmune
therapies and vaccines.
Materials and Methods
OVA and HEL Peptides
Synthetic ovalbumin 323–339 peptide (p323) was purchased
from Anaspec (#62571, Fremont, CA). Custom ovalbumin (OVA)
and hen egg lysozyme (HEL) peptide variants were synthesized by
Peptide 2.0 (Tables 2 and 3, Chantilly, VA). Peptides are named
based on the location of the sequence in the linear protein, with
amino acid residues substitutions indicated. For instance, a peptide
representing residues 328–337 from ovalbumin is termed
OVA328–337, while the same peptide with three extra flanking
residues (two glycines and a valine) on the n-terminus is termed
GGV328–337 and a slightly shorter peptide with three internal
anchor residues substitutions (lysine, isoleucine and valine) is 329-
337KIV. All ovalbumin variants were amidated at the c-terminus.
All peptides were 95% pure or greater as measured by HPLC
analysis, with multiple peptide lots used to confirm results.
Chimeric malE Proteins Containing OVA Epitopes
Fragments of ovalbumin were introduced into the maltose
binding protein (malE) in a manner similar to that first described
by Martineau et al. (1992). These short peptide sequences were
introduced via overlap PCR to replace malE amino acid residues
133–140, flanked at the N-terminus by the amino acids
PDPGSGSG, and at the C-terminus by PDPGS. This extended
linker confers higher protein expression, along with sufficient
length at the N-terminus to preclude contributions from residues
other than glycine or serine during MHC loading. The resulting
chimeric proteins were named based on the numerical OVA
sequence of the inserted peptide. For instance, a chimera
containing all registers of the OVA peptide is termed malE_323–
337. Non-wild type residues introduced into malE_327–337 are
named with respect to register four positions, such that a residue
change from valine to methionine at position P-2 is termed 327 V(-
2)M. The modified malE genes were flanked with directional SfiI
restriction sites and subcloned into pAK400 for periplasmic
expression in E. coli (Krebber et al., 1997). The plasmid was
sequenced to confirm epitope presence, transformed into strain
BL21, grown overnight at 376C in 1–4 L shake flasks. After
replacing spent media with fresh terrific broth, protein expression
was induced with 1 mM IPTG for 4–24 hours at 25 C. The cells
were harvested by centrifugation and cell pellets were resuspended
using ice-cold 0.1 M Tris pH 7.4-buffered 0.75 M sucrose at
3 mL per gram of cell pellet. An osmotic shock to release the
periplasmic contents was performed by addition or 3 mL 1.0 mM
EDTA per gram of cell pellet and approximately 0.3 mg/mL
lysozyme followed by the addition of 6 mM MgCl2 on ice. After
an additional centrifugation step, the supernatant was dialyzed
against 10 mM Tris pH 7.4, 0.5 M NaCl with 12–14 kDa
MWCO dialysis tubing. Chimeric proteins were recovered via
immobilized metal affinity chromatography (IMAC) with the C-
terminal His tag and size exclusion chromatography (Superdex 75;
GE Healthcare) in HBS and stored at 2806C prior to use.
Antigen Presenting and T Cell Hybridoma Cell Lines
The murine A20 B cell lymphoma line presenting I-Ad MHC
was acquired from ATCC (TIB-208). An A20 variant line with a
mutated, non-functional HLA-DMa gene, 3A5 [34,35] was
transferred from Dr. Kenneth Rock, Dana Farber Cancer
Institute, Boston, Massachusetts. The murine DO11.10 T cell
hybridoma line was transferred from Dr. Philippa Marrack,
National Jewish Health Center, Denver, Co. The murine HEL11–
25 responsive T cell hybridoma [25] was a generous gift from Dr.
Andrea Sant, University of Rochester Medical Center, NY. All
cells were maintained in DMEM supplemented with 10% FBS, 50
Units penicillin/50 mg streptomycin per mL and 2 mM L-
glutamine.
T Cell Activation Experiments
Each well of a 96-well plate was seeded with 15,000 A20 cells,
15,000 T cell hydridoma cells and peptide, malE chimera protein
or control peptide/protein per well in DMEM media without L-
glutamine, except where noted. After a 24-hour incubation at
376C, 5% CO2, supernatant was transferred to a new plate and
stored at 2806C prior to IL-2 quantification assays. All peptide/
protein doses were performed in triplicate wells and all experi-
ments replicated at least twice.
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For malE chimeras and control protein experiments, the
relevant protein was thawed, concentrated using 30K molecular
weight cut-off centrifugal filter units (Millipore UFC903024) and
filter-sterilized. Proteins were then quantified via absorbance at
280 nm using a predicted extinction coefficient and molecular
weight, diluted to equal concentrations, the concentration
confirmed and serially diluted in 96-well plates. In each well, the
volume fraction of protein in HBS solution added did not exceed
10%, and an FBS concentration of 10% was maintained in all
wells. Proteins were pre-incubated for four hours with antigen
presenting cells (A20 or 3A5) cells prior to a 24-hour incubation
with T cell hybridomas. The IL-2 concentration in the superna-
tant was quantified using a matched pair ELISA quantified with
an IL-2 standard as described (BD #555148). All experiments
were performed at least twice, and all wells were measured in
triplicate. Data was analyzed with Graphpad Prism 5 (La Jolla,
CA).
Glutamine was excluded from experiments (except where noted)
to minimize cell growth, as preferential growth was observed in
inverse proportion to T cell stimulation. Since overall IL-2 release
is affected by T cell to B cell ratio, and assays were performed only
at a limited number of discrete doses, we reasoned that differential
growth could potentially mask small differences in the activity of
specific peptides. The absence of glutamine lowered overall IL-2
release and required larger concentrations of peptide or protein to
reach a given release.
Predicted Peptide-MHC Docking
The coordinates for I-Ad and the OVA 323–334 peptide were
extracted from PDB 1IAO. The ovalbumin peptide was extended
from the c-terminus to residue 338 and manually extended such
that backbone dihedral angles (w, y) approximate those observed
in an extended polyproline type II helix (275, 150). Computa-
tional peptide docking was performed with ClusPro [36].
Supporting Information
Figure S1 Ovalbumin registers one and three are
predicted as stably associated with I-Ad MHC by
computational docking. Peptide and MHC coordinates of
323–339 and I-Ad were extracted from PDB 1IAO and
computationally docked using Cluspro (Comeau et al, 2004). Shown
are peptide alignments of the register one wild type crystal
structure (green) with the high-scoring ClusPro predicted register
one alignment (blue), and ClusPro predicted register three
alignment (yellow). Registers two and four were not predicted.
(TIF)
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